What Researchers Did
Researchers investigated the efficacy of hyperbaric oxygen therapy (HBOT) in reducing bacterial biofilms using both in vitro experiments and by comparing time-to-healing in chronic wound patients who did or did not receive HBOT.
What They Found
In vitro, hyperbaric oxygen therapy (HBOT) led to small but significant decreases in bacterial cell viability at the 30- and 90-minute time points. In vivo, patients receiving HBOT showed reductions in bacterial load and approximately 1 week shorter treatment durations, though an emergence of anaerobic bacteria and fungi was noted between treatments.
What This Means for Canadian Patients
Hyperbaric oxygen therapy could potentially be used as an adjunctive treatment for Canadian patients with chronic wounds to help reduce bacterial biofilms. This may lead to quicker wound healing times and a reduced risk of complications, improving overall patient outcomes.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
The study's in vitro findings showed only small decreases in cell viability, and the in vivo data was based on a database search, which may have inherent limitations.